1. Home
  2. PRLD vs BRFH Comparison

PRLD vs BRFH Comparison

Compare PRLD & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • BRFH
  • Stock Information
  • Founded
  • PRLD 2016
  • BRFH 2005
  • Country
  • PRLD United States
  • BRFH United States
  • Employees
  • PRLD N/A
  • BRFH N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • BRFH Packaged Foods
  • Sector
  • PRLD Health Care
  • BRFH Consumer Staples
  • Exchange
  • PRLD Nasdaq
  • BRFH Nasdaq
  • Market Cap
  • PRLD 50.1M
  • BRFH 43.8M
  • IPO Year
  • PRLD 2020
  • BRFH N/A
  • Fundamental
  • Price
  • PRLD $0.78
  • BRFH $2.52
  • Analyst Decision
  • PRLD Strong Buy
  • BRFH Strong Buy
  • Analyst Count
  • PRLD 2
  • BRFH 1
  • Target Price
  • PRLD $4.50
  • BRFH $4.50
  • AVG Volume (30 Days)
  • PRLD 110.2K
  • BRFH 7.3K
  • Earning Date
  • PRLD 05-06-2025
  • BRFH 05-01-2025
  • Dividend Yield
  • PRLD N/A
  • BRFH N/A
  • EPS Growth
  • PRLD N/A
  • BRFH N/A
  • EPS
  • PRLD N/A
  • BRFH N/A
  • Revenue
  • PRLD $7,000,000.00
  • BRFH $10,818,000.00
  • Revenue This Year
  • PRLD N/A
  • BRFH $41.20
  • Revenue Next Year
  • PRLD N/A
  • BRFH $42.03
  • P/E Ratio
  • PRLD N/A
  • BRFH N/A
  • Revenue Growth
  • PRLD N/A
  • BRFH 22.03
  • 52 Week Low
  • PRLD $0.61
  • BRFH $1.44
  • 52 Week High
  • PRLD $6.80
  • BRFH $4.61
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 46.96
  • BRFH 44.35
  • Support Level
  • PRLD $0.73
  • BRFH $2.30
  • Resistance Level
  • PRLD $1.00
  • BRFH $2.69
  • Average True Range (ATR)
  • PRLD 0.09
  • BRFH 0.17
  • MACD
  • PRLD -0.01
  • BRFH 0.02
  • Stochastic Oscillator
  • PRLD 18.96
  • BRFH 29.24

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About BRFH Barfresh Food Group Inc.

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

Share on Social Networks: